NAMS NewAmsterdam Pharma Company NV
169
$20.09
$0.04
(0.20%)
| Watchers | 169 |
| 52-Wk Low | $5.63 |
| 52-Wk High | $26.35 |
| Market Cap | $1.81B |
| Volume | 145,782.00 |
| 52-Wk High | $26.35 |
| 52-Wk Low | $5.63 |
NewAmsterdam Pharma Announces Executive Leadership ChangesTipRanks Financial Blog • about 2 months ago
An announcement from NewAmsterdam Pharma Company (NAMS) is now available. NewAmsterdam Pharma Company N.V. has announced Juliette Audet's new role...
Share to Feed
NAARDEN, the Netherlands and MIAMI, April 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or NewAmsterdam or the Company ), a late-stage, clinical biopharmaceutical...
NewAmsterdam Pharma (NASDAQ:NAMS Get Free Report) saw an uptick in trading volume on Tuesday . 195,163 shares changed hands during mid-day trading, a decline of 19% from the previous...
NAARDEN, the Netherlands and MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or NewAmsterdam or the Company ), a late-stage, clinical biopharmaceutical...
Shares of NewAmsterdam Pharma (NASDAQ:NAMS Get Free Report) have been given a consensus rating of Buy by the six research firms that are covering the company, MarketBeat.com...
-- TANDEM is designed to evaluate obicetrapib and ezetimibe fixed-dose combination ( FDC ) as an adjunct to diet and maximally tolerated lipid lowering therapy in patients with HeFH, ASCVD or ASCVD...
NewAmsterdam Pharma (NASDAQ:NAMS Free Report) had its price target raised by Royal Bank of Canada from $25.00 to $31.00 in a report published on Thursday, Benzinga reports. They currently...
-- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 -- -- Plan to initiate TANDEM, pivotal Phase 3 trial evaluating...
NAARDEN, The Netherlands and MIAMI, Feb. 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or NewAmsterdam or the Company ), a late-stage, clinical biopharmaceutical...
Wolverine Asset Management LLC bought a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS Free Report) in the third quarter, Holdings Channel reports. The fund bought 2,925 shares of...